Researchers optimistic about targeted drugs for pancreatic cancer.
McBride
Gail
G
D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D000068258:Bevacizumab; D000068818:Cetuximab; D002986:Clinical Trials as Topic / Q000379:methods; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D017479:Receptors, Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D012107:Research Design; D016019:Survival Analysis
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D015507:Drugs, Investigational; D010879:Piperazines; D011743:Pyrimidines; D000068258:Bevacizumab; D000068877:Imatinib Mesylate; D066246:ErbB Receptors; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor; D000068818:Cetuximab